Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

The oral multi-targeted tyrosine kinase inhibitor (TKI) anlotinib is effective for non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, a fraction of patients remains non-responsive, raising the need of how to identify anlotinib-responsive patients. In the present study, we ai...

Full description

Bibliographic Details
Main Authors: Jun Lu, Qin Shi, Lele Zhang, Jun Wu, Yuqing Lou, Jie Qian, Bo Zhang, Shuyuan Wang, Huimin Wang, Xiaodong Zhao, Baohui Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Oncology
Subjects:
KLK5
L1CAM
anlotinib
non-small cell lung cancer
transcriptome
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00886/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00886/full

Similar Items